Traders Buy Large Volume of Call Options on BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw some unusual options trading on Tuesday. Stock traders acquired 3,961 call options on the stock. This is an increase of 228% compared to the typical volume of 1,206 call options.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on BMRN shares. BMO Capital Markets reiterated an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Wednesday, September 16th. Barclays boosted their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Raymond James Financial raised shares of BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 price objective for the company in a report on Monday, October 12th. Morgan Stanley dropped their target price on shares of BioMarin Pharmaceutical from $124.00 to $122.00 and set an “overweight” rating on the stock in a report on Wednesday, October 21st. Finally, Citigroup increased their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.09.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and in line with expectations. Adjusted EPS was $0.23, well above the consensus estimate for a loss of roughly $0.08–$0.09. Growth was led by a 44% increase in metabolic-condition revenue and a 12% rise in skeletal-condition revenue. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company added a new investigational Fabry disease asset to its clinical portfolio and reported a May 30, 2027 PDUFA action date for VOXZOGO in hypochondroplasia, supporting BioMarin’s longer-term growth story.
• Positive Sentiment: Options activity was notably bullish, with traders purchasing 3,961 call options—about 228% above typical call volume—suggesting increased speculative interest in a potential rebound.
• Neutral Sentiment: Analyst opinion remains mixed. Citi reiterated a Buy rating, while Royal Bank of Canada maintained a Sector Perform rating, indicating that near-term execution concerns are balanced against BioMarin’s pipeline potential.
• Negative Sentiment: BioMarin lowered its 2026 adjusted EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and issued revenue guidance of $3.8 billion–$3.9 billion versus the $3.9 billion consensus. Management cited order-timing uncertainty and charges related to two acquired in-process research programs. BioMarin Q3 2026 Results and Guidance
• Negative Sentiment: Royal Bank of Canada lowered its BMRN price target from $62 to $60 while retaining its Sector Perform rating, reinforcing investor concerns about limited near-term upside.

BioMarin Pharmaceutical Price Performance

Shares of BMRN traded down $2.39 during trading hours on Tuesday, hitting $55.05. 1,527,316 shares of the company were exchanged, compared to its average volume of 2,110,063. The company has a market capitalization of $10.66 billion, a PE ratio of 148.78, a PEG ratio of 0.61 and a beta of 0.22. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The firm has a fifty day simple moving average of $60.43 and a 200-day simple moving average of $58.46. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.31. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter last year, the business posted $0.12 EPS. BioMarin Pharmaceutical’s revenue was up 32.0% on a year-over-year basis. As a group, sell-side analysts predict that BioMarin Pharmaceutical will post 2.59 earnings per share for the current year.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors have recently made changes to their positions in BMRN. Parkside Financial Bank & Trust raised its holdings in shares of BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 187 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in BioMarin Pharmaceutical by 0.5% in the third quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company’s stock valued at $2,407,000 after purchasing an additional 200 shares in the last quarter. North Dakota State Investment Board increased its position in BioMarin Pharmaceutical by 3.9% in the 3rd quarter. North Dakota State Investment Board now owns 5,872 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 218 shares during the last quarter. Chicago Partners Investment Group LLC increased its position in BioMarin Pharmaceutical by 2.4% in the 1st quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock worth $660,000 after purchasing an additional 290 shares during the last quarter. Finally, Signaturefd LLC raised its stake in shares of BioMarin Pharmaceutical by 16.7% during the 3rd quarter. Signaturefd LLC now owns 2,316 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 331 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.